Table 1.

Characteristics of the Study Population at HAART Initiation According to AIDS and FRP Status

	No AIDS Before HAART (N = 472)		AIDS Before HAART (N = 124)		Total (N = 596)
	No FRP* (N = 436)	FRP* (N = 36)	No FRP* (N = 77)	FRP* (N = 47)
Date of HAART initiation†	2/97 (7/96–1/98)	10/96 (5/96–7/97)	6/96 (2/96–1/97)	7/96 (2/96–3/97)	12/96 (5/96–11/97)
Education higher than or equal to college, n (%)	241 (56)	16 (46)	51 (66)	29 (62)	337 (57)
Ethnicity = White non-Hispanic, n (%)	365 (84)	31 (86)	66 (86)	41 (87)	503 (84)
Age†	43 (38–48)	44 (40–49)	43 (39–46)	43 (39–46)	43 (38–48)
Maximum viral load (log10 copies/mL)*,†	4.8 (4.3–5.2)	5.2 (4.6–5.4)‡	5.3 (4.8–5.6)	5.3 (5.0–5.7)	5.0 (4.4–5.3)
Nadir CD4+ cell count (per mm3)*,†	271 (163–388)	239 (86–393)	116 (26–239)	61 (15–170)‡	226 (125–359)
Nadir Hgb before HAART (g/dL)*,†	13.8 (13.1–14.5)	13.2 (11.2–14.2)‡	12.7 (11.8–13.7)	11.4 (10.0–13.1)‡	13.6 (12.5–14.3)
Duration of HIV infection (y)†,§	11.6 (8.5–12.6)	11.5 (8.6–12.0)	11.5 (10.3–12.2)	11.6 (10.6–12.1)	11.6 (8.7–12.5)
Among seroconverting men	7.7 (5.4–11.4)	8.5 (5.6–11.5)	9.0 (7.1–10.9)	9.0 (6.7–10.8)	8.3 (5.6–11.3)
Among seroprevalent men	11.9 (11.0–12.8)	11.8 (11.1–12.4)	11.7 (11.3–12.4)	11.8 (11.4–12.5)	11.8 (11.2–12.7)
HAART responders, n (%)‖	311 (77)	24 (71)	38 (58)	24 (59)	397 (73)
Number of visits assessable for FRP*,†	5 (4–6)	4 (4–6)	4 (3–5)	4 (3–5)	4 (4–6)
>25% manifesting FRP visits, n (%)*	0	18 (50)	0	28 (60)	46 (8)

Notes: FRP = frailty-related phenotype; HAART = highly active antiretroviral therapy; Hgb, hemoglobin.

^*Within the 3 years before HAART.

^†Median (interquartile range).

^‡p ≤ ·05 when comparing men with FRP with those without FRP at HAART initiation FRP.

^§Durations calculated from estimated date of seroconversion for seroconverting men (N = 178) and from first HIV-positive visit for seroprevalent men (N = 418).

^‖Defined as a viral load of <1,000 copies/mL within 1 year after starting HAART, % are based on nonmissing data.